The optimum intensity of conditioning therapy in patients aged 40-60 years with AML and myelodysplastic syndrome (MDS) undergoing allogeneic haematopoietic cell transplantation (alloHCT) remains uncertain. We compared outcomes of reduced intensity conditioning (RIC) and conventional intensity conditioning (CIC) in 101consecutive patients (CIC, 62; RIC, 39) with AML and MDS aged 40-60 years undergoing alloHCT from 2002 to 2008 at our centre. The median age, unrelated transplants and co-morbidity index were higher in the RIC group. Median OS and EFS were 31.0 months (95% confidence interval (CI): 12.8-59.3) and 20.7 months (95% CI: 11.0-30.4), respectively, with no significant difference between the two cohorts. The 3-year treatmentrelated mortality (TRM) and relapse were 28% (95% CI: 21-39) and 25% (95% CI: 17-36), respectively, with no significant difference between the two cohorts. No difference in OS, EFS, TRM or relapse was observed between the two cohorts in the multivariate model. Only disease risk was significantly associated with OS (Hazard ratio (HR): 1.85, CI: 1.01-3.45), EFS (HR: 1.73, 95% CI: 1.00-3.10) and cumulative relapse (HR: 3.24, 95% CI: 1.08-10.12). Disease biology rather than intensity of conditioning regimen seems to determine outcomes of alloHCT in patients aged 40-60 years with AML/MDS.
Introduction
The curative advantage of allogeneic haematopoietic cell transplantation (alloHCT) as a consolidative approach in myeloid malignancies is offset by the high treatment-related mortality (TRM) seen with conventional intensity conditioning (CIC) regimens. In response to the high TRM of CIC regimens, investigators have developed and tested reduced intensity conditioning (RIC) regimens. One European Group for Blood and Marrow Transplantation study 1 of 315 RIC and 407 CIC patients over 50 years of age with AML reported that acute GVHD and TRM were significantly decreased in RIC group (relative risk (RR): 0.60 with 95% confidence interval (CI): 0.4-0.88; RR: 0.48 with 95% CI: 0.33-0.68, respectively) at the expense of a significant increase in the incidence of relapse (RR: 1.78 with 95% CI: 1.3-2.43). A larger study by the Center for International Blood and Marrow Transplant Research 2 compared 1500 RIC and 3731 CIC transplants from multiple centres. Relapse rate was significantly higher in the RIC group (RR: 1.32, 95% CI: 1.19-1.46). Although the early TRM was higher in the CIC group (RR: 1.55, 95% CI: 1.20-1.99), neither the 5-year TRM (P ¼ 0.48) nor OS (RR: 1.05, P ¼ 0.25) differed between the two groups. These registry studies were limited by lack of information on comorbidities and the decision-making process. The extent to which conditioning regimens vs differing patient characteristics were responsible for outcomes is, therefore, uncertain.
Most transplant physicians would recommend RIC over 60 and CIC below 40 years; however, the optimum intensity between 40 and 60 years remains controversial. We, therefore, retrospectively compared CIC and RIC regimens in patients aged 40-60 years with AML and myelodysplastic syndrome (MDS) receiving matched sibling or unrelated alloHCT. We collected co-morbidity data and used an earlier validated index to adjust for the differences.
Patients and methods
We included consecutive patients, aged 40-60 years, diagnosed with AML or MDS who had undergone first alloHCT between January 2002 and June 2008 at the Princess Margaret Hospital. This retrospective study was approved by Cancer Registry Data Access Committee and Research and Ethics Board of the University Health Network.
AML was defined as high risk for relapse if at least one of the following factors existed: poor-risk cytogenetics as defined by SWOG/ECOG, 3 need for more than a single course of treatment to achieve remission, 4 a preceding haematological disorder or therapy-related AML and AML in second CR with first CR duration o1 year. All other AML patients were considered as standard risk. For patients with MDS, high-risk disease was defined by any of the following: therapy-related MDS or if the International Prognostic Scoring System 5 was X1.5. All other MDS patients were classified as standard risk.
Data on co-morbidities were collected and scored according to the HCT-specific co-morbidity index (HCT-CI). 6, 7 Performance status was collected and scored according to the Karnofsky performance score. 8 The day of neutrophil recovery was defined as the first of 3 consecutive days with an ANC of X0.5 Â 10 9 /L for at least 3 consecutive days. The day of platelet recovery was defined as the first of 7 consecutive days with a peripheral platelet count of 420 Â 10 9 /L without transfusion. Acute and chronic GVHD was staged and graded according to earlier established criteria. 9, 10 For chronic GVHD, data were retrospectively reviewed and patients were scored according to the traditional criteria 11 and the recently published National Health Institute criteria. 12 Relapse was defined as haematological recurrence of disease in blood, BM or extra-medullary sites. The cause of death was classified based on criteria suggested by Copelan et al.
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Treatment
Patients were admitted to an HEPA-filtered, single room for the purpose of transplantation irrespective of intensity of conditioning therapy. All cases were discussed in an allogeneic transplant meeting and the decision regarding intensity of conditioning therapy was based on consensus of the meeting after reviewing age, co-morbidities and performance status. During the study period, AML patients were only transplanted if they had BM blasts of o5%. Classification of the intensity of conditioning therapy was based on the Center for International Blood and Marrow Transplant Research suggested criteria.
14 The reduced intensity regimen used in our study consisted of Fludarabine (30 mg/m 2 /day X4) and BU (3.2 mg/kg/day X2 intravenously) with 200 cGy of TBI. The conventional intensity regimens used were IV Bu-Cy, 15 CY-TBI, 16 AraC-CY-TBI 17 and Flu-IV Bu-TBI 18 with no thymoglobulin. GVHD prophylaxis was CyA/MTX 19 or CyA/MMF 20 in related donor transplants and Alemtuzumab/CyA 21 in unrelated donor transplants (10 of 20 patients in CIC group and all 21 patients in RIC group). GVHD prophylaxis was continued until day 120 for related and unrelated donor transplants, then tapered rapidly if there were no sign of GVHD. Acute GVHD was treated with prednisone 1 mg/kg for grade 2, and 2 mg/kg for grades 3-4. The first line of treatment of chronic GVHD was prednisone 1 mg/kg with slow tapering as described. 22 Patients who started steroids for the treatment of GVHD also started antifungal prophylaxis in the form of Fluconazole 150 mg once weekly, calcium, vitamin D and an oral bisphosphanate for osteoporosis prophylaxis. All patients received PCP prophylaxis (single-strength two tablets of trimethoprim-sulfamethoxazole thrice per week or pentamidine inhalation 300 mg every 4 weeks) for up to 1 year after transplantation, but longer if a patient was still receiving immunosuppressants. Transfusion and other supportive care were also carried out as earlier described. 23, 24 Patients who received Alemtuzumab as part of their GVHD prophylaxis also received 3 months of antifungal prophylaxis (voriconazle, itraconazole or posaconazole) and antiviral prophylaxis (acyclovir). Post transplant G-CSF was not routinely administered.
Statistical analyses
Descriptive statistics were reported as median and range for continuous variables and frequencies and proportions for categorical variables. Fisher's exact test and Pearson's w 2 test were used to compare proportions. Wilcoxon's ranksum test was used to compare the continuous variables. Cumulative incidences of relapse, TRM, acute GVHD and chronic GVHD were calculated to account for competing risks. 25 EFS and OSs were calculated using the KaplanMeier method. OS was defined as the time from transplantation date till death from any cause. EFS was defined as the time from transplantation to relapse or death from any cause. Cumulative TRM was calculated as the incidence of deaths not related to relapse. Differences between survival curves were analysed by the log-rank test. The Cox proportional hazard regression model was applied for multivariate analysis that included independent variables age (continuous), type of donor (related, unrelated), Karnofsky performance score (continuous), disease risk (high risk, standard risk), HCT-CI score (0, 1-2, X3) and conditioning regimen (RIC vs CIC). The results were considered significant if the P-value is X0.05. The analysis of competing risk was applied using the Cmprsk package in R software (The R Foundation, Vienna, Austria). All the other analyses were performed with SAS 9.1 (SAS Institute, Cary, NC, USA).
Results
There were 101 patients eligible for the study; 62 in the CIC and 39 in the RIC group. As shown in Table 1 , baseline characteristics were similar except for age, donor type and a trend in co-morbidity. Median age was higher in the RIC group at 53 years, compared with 50 years in the CIC group. As expected, more patients with a higher co-morbidity index were seen in the RIC group; however, the P-value was not significant. Median follow-up was 16.6 months (0-76.4) for all patients and 34.3 months (3.3-76.4) for surviving patients.
OS and EFS
We observed a total of 49 deaths. The median OS for both groups was 31.0 months (95% CI: 12.8-59.3) with 3-year survival probability 0.51 (95% CI: 0.41-0.61). Median OS was 23.2 and 31.0 months in the RIC and CIC groups, respectively (Hazard ratio (HR): 1.20, 95% CI: 0.67-2.17; Figure 1a ). In the multivariable Cox model, the only statistically significant factor was disease risk (HR: 1.85, 95% CI: 1.01-3.45). The 49 deaths were due to a variety of causes: disease relapse/progression (18 patients), infection (9), GVHD (15), graft failure (1) and direct regimenrelated toxicities (2) . The causes of the four remaining deaths are unknown (all were in remission). The results of the univariable and multivariable analyses are shown in Tables 2 and 3, respectively. Fifty-two patients either relapsed or died during the study period. The median EFS for the whole group was 20.7 months (95% CI: 11.0-30.4) with a 3-year probability of 0.47 (95% CI: 0.36-0.57). The median EFS was not statistically different between the two treatment groups (CIC 21.7, RIC 19.6 months, HR: 1.06, 95% CI: 0.60-1.86; Figure 1b ). Using the multivariable Cox model, only disease risk was a statistically significant variable identified by this model (HR: 1.73, 95% CI: 1.00-3.10).
TRM and relapse
The 3-year cumulative incidence of TRM was 0.28 (95% CI: 0.21-0.39). The incidence was not statistically different between the two treatment groups (HR: 0.75, 95% CI: 0.34-1.64; Figure 2a ). In the multivariable Cox model, none of the factors specified a priori were statistically significant. The 3-year cumulative incidence of relapse was 0.25 (95% CI: 0.17-0.36) with no significant difference between the CIC and RIC groups, HR: 1.25 (95% CI: 0.56-2.82; Figure 2b ). Using the multivariable Cox model, only disease risk was significant with a relatively large HR of 3.24 (95% CI: 1.07-9.82).
Haematopoietic recovery, regimen-related toxicities and GVHD The duration of cytopenias was different between the two treatment groups. Median duration of neutropenia was significantly shorter in the RIC compared with the CIC group, 12 (range: 5-20) vs 16 (7-53) days, Po0.0001. Similar findings were seen in the duration of thrombocytopenia. Median duration was only 2 days (1-7) in the RIC group, which was significantly shorter than in the CIC group, 9 days (1-49) with a P-value of 0.0007. Except for stomatitis, there was no difference in the regimen-related toxicities developed by week 6 between the CIC and RIC groups measured using Bearman criteria 26 (Table 4) . Fifty and eight patients developed stomatitis grade X2 in the CIC and RIC groups, respectively, Po0.0001. The cumulative incidence of acute GVHD at day 100 was 0.72 (95% CI: 0.63-0.82) with no significant difference between Extensive chronic GVHD was seen in 37 and 18 patients, respectively. These differences were not statistically different between the two treatment groups. Using the recently suggested National Health Institute criteria for the assessment of chronic GVHD, there was no statistically significant difference in the global score of the two treatment groups, P ¼ 0.81.
Discussion
The outcomes from RIC transplants in our study were similar to the CIC transplants despite their having worse prognostic factors including a higher proportion of older patients, unrelated transplants and a trend towards a higher co-morbidity score. OS, EFS, cumulative incidences of TRM, acute GVHD, chronic GVHD and relapse were similar with no statistically significant differences between the two treatment groups. In the multivariable Cox model, the only factor that was statistically significant was diseaserisk stratification for OS, EFS and cumulative incidence of relapse. Overall, these results are very similar to the report by Lim et al. 27 in patients of 50 years or older; where the disease stage at transplantation was the main independent factor predicting poor 4-year OS, HR, 1.55 (95% CI: 1.32-1.83).
We limited our study to patients between 40 and 60 years of age as the optimum conditioning regimen in this age group remains controversial. Most patients younger than 40 years tolerate the CIC regimens well and may benefit from both the chemo-intensity and GVL effect of the allogeneic BMT. Owing to very high TRM, patients older than 60 years are mostly considered unsuitable for CIC regimens. 28 A survival advantage for RIC allogeneic BMT vs the CIC approach has not been shown yet except for in one study 29 similar in size to ours. Most of the other studies 30, 31 did not show any difference in survival. Possible reasons for failure to show a survival difference in these studies include a higher relapse rate using RIC regimens, 32 31 in patients younger than 50 years. In our study, the reduced intensity regimen used falls within the higher spectrum of intensity of RIC regimens and may explain the relatively higher TRM. The lack of predictive significance of the co-morbidity score in our study is likely to be related to the small sample size. In addition, compared with the study by Sorror et al., 6 our study population only included patients aged 40-60 years in which the co-morbidity index may not be as significant as in patients over 60 years of age.
The results should be interpreted in the light of the study limitations. Sample size is small and median follow-up is relatively short. The HRs have wide confidence intervals and could include a large benefit favouring either approach. The results of such retrospective design can be significantly influenced by differences in patient characteristics related to prognosis that drive the decision of whether to use RIC or CIC. 33 Patients with co-morbidities could have been assigned to RIC regimens, whereas those with higher-risk disease were assigned to the CIC regimens according to the discretion of treating physicians. This should have resulted in a higher TRM in the RIC group unless the RIC regimens truly lowered it, which is likely given the higher co-morbidity score difference between the two groups. In our multivariable modelling, we have chosen the clinically relevant factors that have earlier been shown to be prognostic in these settings, but the number of factors was limited by the sample size.
Strengths of this study include the collection of comorbidity and disease-risk data and using multivariable regression modelling to adjust for the baseline differences in these two factors. Many of the other registry studies do not measure and adjust for co-morbidities. The comorbidity index used is one that has been earlier used and validated in the allogeneic BMT settings. In addition, the study population is more homogeneous than those of the registry studies.
In conclusion, the results of our study suggest that disease risk rather than intensity of conditioning predicts outcome in patients with AML/MDS aged 40-60 years undergoing alloHCT. The intensity of the conditioning regimen in this age group remains the choice of the treating physician and the patient. Prospective randomized trials are needed to further address this issue.
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